Denufosol and Azithromycin Inhalation for Cystic Fibrosis Lung Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cystic fibrosis, particularly those involving macrolides like azithromycin, often cause significant adverse effects, especially gastrointestinal issues, which can interfere with nutrient absorption and other medications, and are not sufficiently effective in improving lung function.
Innovation Solution
Administering denufosol, a P2Y2 receptor agonist, in combination with a macrolide, such as azithromycin, either sequentially or concurrently, primarily through inhalation, to enhance mucociliary clearance and lung function without the adverse effects associated with systemic administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If macrolides like azithromycin are administered orally to treat cystic fibrosis, then lung function is improved, but significant gastrointestinal adverse effects occur that interfere with nutrient absorption and other medications
Solution Approach 1:
The patent applies local quality by switching from oral administration (systemic distribution) to inhaled administration (local delivery to lungs). This concentrates the therapeutic effect in the lungs while minimizing exposure to the gastrointestinal tract, thereby improving lung function without causing gastrointestinal adverse effects.
Solution Approach 2:
The patent uses an inhaled formulation as an intermediary delivery system. Instead of oral administration that passes through the gastrointestinal tract, the macrolide is delivered via inhalation, using the respiratory system as an intermediary pathway to reach the lungs directly, avoiding gastrointestinal side effects.
2Reliability
If higher doses of macrolides are administered to improve therapeutic effectiveness, then lung function improvement increases, but adverse effects become more severe
Solution Approach 1:
By administering macrolides through inhalation rather than oral route, the patent achieves high local concentration in the lungs with lower systemic exposure. This allows for effective therapeutic doses to be delivered to the target site without proportionally increasing adverse effects throughout the body.
Solution Approach 2:
The patent changes the administration route parameter from oral to inhaled, which fundamentally alters the pharmacokinetic profile. This parameter change enables higher local drug concentration at the site of action while reducing systemic side effects, effectively decoupling therapeutic effectiveness from adverse effects severity.
3Reliability
If macrolides are administered to treat cystic fibrosis, then pulmonary exacerbations are reduced, but gastrointestinal side effects interfere with absorption of nutrient and other medications
Solution Approach 1:
The patent applies local quality by delivering macrolides directly to the lungs through inhalation, concentrating the therapeutic effect where needed while avoiding the gastrointestinal tract. This preserves gastrointestinal function and absorption capabilities while still achieving reduction in pulmonary exacerbations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combined administration of denufosol and a macrolide effectively improves lung function and reduces pulmonary exacerbations, offering better therapeutic outcomes than single-agent treatments while minimizing side effects by delivering high concentrations directly to the lungs.
Implementation Method 1
P2Y2 agonists act by stimulating the P2Y2 receptor, which results in the secretion of chloride ion (Cl−) and liquid and the inhibition of sodium (Na+) absorption to hydrate the airway surface liquid layer
Implementation Method 2
Administering denufosol, a P2Y2 receptor agonist, in combination with a macrolide, such as azithromycin, either sequentially or concurrently, primarily through inhalation
Data Source
AI summary
The present invention is directed to a method for treating cystic fibrosis. The method comprises the steps of: identifying a patient suffering from cystic fibrosis, and administering to the patient an effective amount of denufosol or a pharmaceutically acceptable salt thereof and an effective amount of a macrolide. In one method, denufosol and the macrolide are administered by inhalation, preferably in a single formulation. In another method, denufosol is administered by inhalation and the macrolide is administered orally. The present invention is also directed to a pharmaceutical formulation comprising denufosol or a pharmaceutically acceptable salt thereof, a macrolide, and a pharmaceutically acceptable carrier. Preferred denufosol is denufosol tetrasodium and preferred macrolide is azithromycin. The pharmaceutical formulation preferably is in a form of an inhalable dry powder or in a liquid form.